Cystic Fibrosis and Penicillin Hypersensitivity

McDonnell, Tim; Fitzgerald, M. X.

doi:10.1016/s0140-6736(84)92487-5

Cited by 12 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of Pseudomonas aeruginosa (P. aeruginosa) increases with age and approaches 80% in adults with CF [2]. The current recommended treatment for pulmonary exacerbations of P. aeruginosa includes the combination of intravenous beta-lactam antibiotic and an aminoglycoside for reactions to beta-lactam antibiotics in patients with CF (≥ 29%) [6][7][8][9][10][11][12][13]. The highest reported prevalence was reported in Danish patients where over 60% of patients had an allergic reaction to one or more beta-lactam antibiotics [11].…”

Section: Introductionmentioning

confidence: 99%

Beta-lactam allergy in adults with cystic fibrosis

Burrows

Nissen

Kirkpatrick

et al. 2007

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Beta-lactam allergy in adults with cystic fibrosis

Burrows

Nissen

Kirkpatrick

et al. 2007

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…In patients with cystic fibrosis, the prevalence of adverse reactions to piperacillin appears to be high. This observation might be explained by the frequent use of complex penicillins in combination with a hyperimmune state in patients with cystic fibrosis [7]. Since the 1960s, hemolysis has been described as a serious complication of penicillin therapy [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Immune-Mediated Severe Hemolytic Crisis with a Hemoglobin Level of 1.6 g/dl Caused by Anti-Piperacillin Antibodies in a Patient with Cystic Fibrosis

et al. 2010

View full text Add to dashboard Cite

We report a 23-year-old female patient with cystic fibrosis developing severe intravascular hemolysis with a minimal hemoglobin level of 1.6 g/dl after 7 days of treatment with piperacillin, consistent with an immune-mediated hemolytic crisis. Twenty days later, the patient could leave the hospital in good condition without any neurological deficit. To our knowledge, this is the lowest reported hemoglobin value caused by hemolytic anemia with intact survival. As piperacillin is commonly used in patients with cystic fibrosis, it is important to monitor the full-blood counts of patients during treatment with piperacillin and to be aware of the potential for hemolytic anemia to develop. Anti-piperacillin antibodies should be considered whenever these patients develop hemolytic anemia or a positive direct antiglobulin test (DAT). Furthermore, drug-fever under piperacillin application could be a warning sign for the development of hemolytic anemia.

show abstract